Introduction {#s1}
============

Circular RNAs (circRNAs), a novel class of endogenous covalently closed RNA molecules, have attracted great attention in the past few years. They are generally derived from back-splicing of precursor mRNA (pre-mRNA), during which the 3′ splice donor sequence is joined to the downstream 5′ splice acceptor sequence ([@B1], [@B2]). In 1976, Sanger et al. ([@B3]) first identified the single-stranded viroid RNA in circular formats with high thermal stability *via* electron microscopy. Subsequently, this kind of circRNA transcript was found in hepatitis delta virus ([@B4]), yeast ([@B5]), archaea ([@B6]), fruit flies ([@B7]), and mammals ([@B8]). In 1991, Nigro et al. ([@B9]) discovered the presence of circRNA transcripts derived from the Deleted in Colon Cancer (DCC) gene in humans for the first time; subsequently, other genes, including ETS-1 gene ([@B10]), the human cytochrome P450 gene ([@B11]), the human dystrophin gene ([@B12]), and the antisense noncoding RNA in the INK4 locus ([@B13]), were identified to produce circular transcripts. However, these circRNAs were long considered as aberrant splicing by-products with low abundance and limited biological function ([@B14]).

With the development of high-throughput RNA sequencing (RNA-seq) and bioinformatics tools, numerous circRNAs have been identified. Salzman et al. ([@B15]) explored the circRNA map in pediatric acute lymphoblastic leukemia samples and revealed that large portions of spliced gene transcripts are circRNAs. Jeck et al. ([@B16]) identified \>25,000 circRNAs that are not degraded by exonucleases in human fibroblasts. Circular splicing of RNA is accepted to be a general feature of gene expression, but whether these circRNAs are functional is a primary concern of researchers.

Studies to date have reported that circRNAs are dysregulated in the pathophysiologic processes of several diseases, including cardiovascular disease ([@B17]), neurodegenerative disease such as Alzheimer\'s disease ([@B18]), metabolic disorder ([@B19]), diseases caused by viral infection ([@B20]), and cancer, which is the focus of the following sections ([@B21]). Abnormal expressed circRNAs can modulate gene transcription *via* indirect interactions with other transcription factors, such as microRNAs (miRNAs) and RNA binding proteins (RBPs) ([@B22], [@B23]). Sporadic studies have also pointed out that some circRNAs containing translation initiation elements can be translated into functional proteins and peptides ([@B24], [@B25]). Moreover, the competitive splicing mechanism of circRNAs also affects the expression of their parent genes, thus producing biological effects ([@B26]). In addition to functioning as regulators of gene expression, circRNAs are also novel promising biomarkers for disease diagnosis and prognosis assessment due to their stable closed circular structure and tissue- and developmental stage-specific expression patterns ([@B27], [@B28]).

However, the understanding of circRNAs is in its infancy, and knowledge of the biological characteristics of these molecules requires further supplementation. More work is needed to explore the emerging roles of circRNAs in cancer. In this review, we introduce the biogenetic model, expression profile, and functional mechanism of circRNAs and summarize recent progress in circRNA research and their application in cancer.

Mechanisms for circRNA Generation {#s2}
=================================

circRNAs are divided into three main types according to their sources, namely, exonic circular RNAs (ecircRNAs), circular intronic RNAs (ciRNAs), and exon--intron circular RNAs (elciRNAs), among which ecircRNAs are the most common ([@B29]). Several circularization mechanisms produce circRNAs. These elements shorten the spatial distance between the two ends of the loop sequence and provide possibilities for back-splicing.

Intron pairing-driven circularization is mediated by 30--40 nucleotide (nt) reverse complementary sequences in the flanking regions of circularized exons; these sequences form double-stranded RNA structures and therefore promote circRNA production as cis-acting elements ([@B2], [@B16]). Alu is the most common reverse complementary element in mammals. In addition, some specific RBPs can bind to both sides of flanking intron sequences and bring splice donors and splice acceptors sufficiently close through protein--protein interactions ([@B30]), such as Quaking (QKI) ([@B31]), NF90/NF110 ([@B32]), and FUS ([@B33]). In contrast, other RBPs may inhibit circRNA production. For example, adenosine deaminase acting on RNA 1 (ADAR1), a common Alu editing element, was identified to deaminate adenosine nucleosides to inosine (A-to-I editing) in regions that complementary and proximal to the splice sites of circularized exons and destabilize intron pairing interactions, thereby antagonizing circRNA biogenesis ([@B34]). Lariat-driven circularization occurs in the process of exon skipping. This process produces a lariat intermediate containing introns and exons, which then undergo back-splicing to form circRNAs. The production of ciRNAs is a special situation in the lariat-driven model ([@B35]). CircRNA biogenesis *in vivo* is indeed very complicated. The expression level of a circRNA may be influenced by various circularization mechanisms. In addition, alternative splicing is a key component of circRNA production and gene expression regulation ([@B36], [@B37]).

circRNA Expression and Characteristics {#s3}
======================================

circRNAs have been identified to be expressed widely in most organisms. The size of circRNAs ranges from \<100 to several thousand nucleotides ([@B30]), and the common size reported in human cells is a few hundred nucleotides comprising 2--3 exons. The expression of most circRNAs is generally lower than that of their linear transcripts ([@B38]), but a few circular transcripts exhibit an expression level slightly or much higher than those of the their linear transcripts, such as the products of the CDR1 and Sry genes ([@B8], [@B15], [@B16], [@B22]). In addition, due to their unique closed circular structure, circRNAs are protected from degradation by exonucleases and are more stable than linear RNAs ([@B16]). Multiple studies have reported that circRNAs have longer half-lives than linear transcripts both *in vitro* and *in vivo* ([@B39], [@B40]). Moreover, circRNA expression is generally tissue- and developmental stage-specific. Several studies have shown that many circRNAs are upregulated in the nervous system ([@B41]--[@B44]), a characteristic that may be related to their posttranscriptional accumulation in neurons ([@B45]--[@B47]). Therefore, scientists hypothesized that the intracellular level of circRNAs was negatively correlated with the cell proliferation index ([@B48]). This hypothesis may explain why circRNA expression in tumor cells is generally lower than that in normal cells. Moreover, circRNAs may have higher sequence conservation than other types of RNA in mammals ([@B41]). Taken together, the high conservation, stability, and specificity of circRNAs imply that circRNAs may have multiple biological functions and clinical applications and are unlikely to be simply splicing by-products.

Techniques for Studying circRNAs {#s4}
================================

Although circRNAs were discovered decades ago, they could not be detected by early routine poly(A)-enriched RNA sequencing technology. Panda et al. ([@B49]) proposed a novel method, RNase R treatment followed by polyadenylation and poly (A)+ RNA depletion (RPAD), to enrich highly pure circRNAs. In this method, total RNAs are first treated with RNase R to deplete linear RNAs. The remaining RNAs with 3\'-OH ends are polyadenylated and removed by poly (A)+ RNA depletion *via* oligo (dT) beads. The RPAD method eliminated the interference of linear RNAs and significantly improved the reliability of the data. However, RPAD is unsuitable for joint analysis of circRNAs with other molecules such as miRNAs and mRNAs. Researchers should adopt different methods to optimize RNA sequencing libraries for the specific experimental purpose.

To date, a variety of algorithms have been developed to identify circRNAs. CircRNAs are generated primarily from pre-mRNA back-splicing, not canonical splicing; thus, the mapping algorithms used in early transcriptome analysis cannot directly match the fragments to the genome. Therefore, sequencing reads that span back-splicing sites require further genomic alignment and correction ([@B50], [@B51]). Various bioinformatics algorithms have been developed for circRNA annotation and quantification ([@B51], [@B52]). The use of two or more tools simultaneously is recommended to meet specific research demands for circRNA identification ([@B52]). In addition, multiple databases have been developed for circRNA analysis ([Table 1](#T1){ref-type="table"}). Through these databases, researchers can search basic information about circRNAs, predict interactions of circRNAs with target molecules and their translation potential, and evaluate their relationships with diseases.

###### 

Databases about circRNAs.

  **Database**      **Website**                                           **Function**                                                                                                                                                                                 **References**
  ----------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Circbase          <http://www.circbase.org/>                            Circbase collects and integrates published circRNA data and identifies circRNAs in sequencing data by find_circ software                                                                     ([@B53])
  CIRCpedia v2      <http://www.picb.ac.cn/rnomics/circpedia>             CIRCpedia contains transcriptome data from approximately 180 samples across six species and systematically annotates alternative back-splicing and alternative splicing events of circRNAs   ([@B36])
  DeepBase v2.0     <http://rna.sysu.edu.cn/deepBase/>                    DeepBase v2.0 collects a total of 107,913 circRNAs, of which 92.5% were found in human                                                                                                       ([@B54])
  CircRNADb         <http://202.195.183.4:8000/circrnadb/circRNADb.php>   CircRNADb provides not only basic information about the chromosomal position and sequences of circRNAs but also the information about their protein-coding potential                         ([@B55])
  TSCD              <http://gb.whu.edu.cn/TSCD>                           TSCD collects tissue-specific circular RNAs in humans and mice                                                                                                                               ([@B56])
  CircInteractome   <http://circinteractome.nia.nih.gov/>                 CircInteractome provides information about microRNA and RBP binding sites on circRNAs and can design specific primers and siRNA for circRNA experiment verification                          ([@B57])
  CSCD              <http://gb.whu.edu.cn/CSCD/>                          CSCD collects circRNA data from 87 cancer cell lines and 141 normal cells, describing cancer-specific circRNA                                                                                ([@B58])
  Circ2Traits       <http://gyanxet-beta.com/circdb/>                     Circ2Traits integrates 1,954 circular RNAs related to human diseases. The included circRNA contains disease-related SNPs or can interact with disease-related miRNAs                         ([@B59])
  MiOncoCirc        <https://nguyenjoshvo.github.io/>                     MiOncoCirc collects the data of circRNA expression in different cancer clinical samples                                                                                                      ([@B60])
  ExoRBase          <http://www.exorbase.org/>                            ExoRBase collects 58330 circRNAs from 92 serum exosomal RNA sequencing samples                                                                                                               ([@B61])

*circRNA, circular RNA; RBP, RNA binding protein*.

Functions of circRNAs {#s5}
=====================

Numerous reports have confirmed that circRNAs can regulate gene expression directly or, more commonly, through binding with miRNAs, RBPs, and other gene expression regulators, thereby regulating various biological processes.

miRNA Sponging
--------------

miRNAs are a large class of small (\~22 nt) noncoding single-stranded RNAs that can bind to their target mRNAs to inhibit their translation or promote their degradation. Recent studies have reported that many circRNAs can act as competitive endogenous RNAs (ceRNAs), binding with miRNAs through miRNA response elements (MREs) to downregulate the function of the target miRNA. The most representative example is CDR1as (antisense to the cerebellar degeneration-related protein 1 transcript), also known as ciRS-7 ([@B22], [@B62]). CDR1as contains 73 binding sites for miR-7, and the interaction of these two RNAs can inhibit the function of miR-7. In addition, their interaction provides a novel mechanism for miR-7 transport. Similarly, circSry, derived from the mouse sex-determining gene Sry, contains 16 binding sites for miR-138 and can act as a miRNA sponge ([@B29]). Notably, most ecircRNAs are localized mainly in the cytoplasm, indicating their availability to bind with miRNAs and regulate their function ([@B39]). However, most circRNAs do not contain multiple miRNA binding sites ([@B29]). Although this mechanism is the most widely studied mechanism of circRNAs, its importance remains to be confirmed. The abundance of most circRNAs is generally low, which also limits the universality of the miRNA sponge hypothesis.

Protein Scaffolding
-------------------

CircRNAs contain many RBP binding sites in addition to MREs. For example, human antigen R (HuR) has been reported to bind with numerous circRNAs in human cervical carcinoma HeLa cells ([@B63]). CircPABPN1, derived from the PABPN1 gene, can compete with PABPN1 mRNA for binding to HuR, thereby inhibiting the translation of PABPN1. In addition, elciRNAs and ciRNAs, predominantly localized in the nucleus, were shown to be able to interact with small nuclear ribonucleoprotein U1 (snRNP U1) and enhance RNA polymerase II (Pol II) transcriptional activity on their parental gene as cis regulators ([@B35], [@B64]). Additionally, the binding of circRNAs to some functional proteins may affect multiple signaling pathways leading to homeostasis changes. Du et al. ([@B65]) found that the circRNA circ-Foxo3 interacted with the anti-senescence protein ID-1, the transcription factor E2F1, and the anti-stress proteins FAK and HIF1α and retained them in the cytoplasm to hinder their corresponding functions.

Translational Templates
-----------------------

Although circRNAs have historically been considered noncoding RNAs, several recent studies have indicated that some circRNAs contain translation initiation sites and have translational potential ([@B39]). For example, some circRNAs with internal ribosome entry sites (IRESs) can be translated into proteins *in vitro* and *in vivo* ([@B24]). FBXW7-185aa is a novel protein encoded by circ-FBXW7 and contains an IRES ([@B66]). N6-methyladenosine(m6A), the most common RNA base modification, is abundant in circRNA sequences and can facilitate translation initiation by recruiting eIF4G2 and YTHDF3 ([@B67]). Another study in 2017 found that circ-ZNF609 contained an open reading frame and could be translated in human skeletal muscle. To date, only a few circRNAs have been reported to be involved in the translation process. Although some bioinformatics tools have been developed to predict the translation potential of circRNAs, their accuracy needs to be further improved and experimentally verified. In addition, whether these proteins or peptides formed from circRNAs have important functions needs exploration.

Other Functions
---------------

Moreover, the biosynthesis of circRNAs can compete with the splicing of their linear transcripts, thus affecting their expression and corresponding functions ([@B68]). Because of their stability, circRNAs can also accumulate over time and may thus act as memory molecules for the transcriptional history of a cell ([@B69]). The presence of circRNAs in vesicles also suggests their function as signaling molecules ([@B70]).

The Functions of circRNA and Cancer {#s6}
===================================

CircRNAs are abnormally expressed in many cancers, such as lung cancer, breast cancer, digestive system cancers, ovarian cancer, and glioblastoma. Hang et al. ([@B71]) identified 185 differentially expressed circRNAs between non-small-cell lung cancer (NSCLC) tissues and adjacent normal tissues through RNA sequencing. In addition, Zeng et al. ([@B72]) detected 192 upregulated and 239 downregulated circRNAs in colorectal cancer (CRC) tissues from patients with or without pulmonary metastasis. Whether this differential expression is related to cancer development has been a focus of circRNA research.

Cell Proliferation
------------------

*Via* high-throughput sequencing, Xie et al. ([@B73]) screened a circRNA related to bladder cancer (BC), BCRC-3. BCRC-3 is poorly expressed in BC tissues and cell lines, and it can bind to miR-182-5p to act as a ceRNA, thereby upregulating the expression of p27 and inhibiting BC cell proliferation. Liang et al. ([@B74]) found that circβ-catenin was upregulated in liver cancer tissues compared to adjacent tissues. Silencing circβ-catenin significantly inhibited malignant phenotypes. Mechanistically, circβ-catenin can be translated into a 370-amino acid (aa) β-catenin isoform. This β-catenin−370aa construct competed with GSK3β to inhibit its degradation of β-catenin, thereby activating the Wnt/β-catenin pathway in liver cancer to promote tumor growth. Moreover, circACC1 has been reported to bind the regulatory β and γ subunits of AMP-activated protein kinase (AMPK), resulting in a ternary complex, which in turn activates AMPK enzyme activity and then promotes fatty acid b-oxidation and glycolysis ([@B75]). Overexpression of circACC1 can promote tumorigenesis. A positive correlation between AMPK activation and elevated circACC1 expression was identified in CRC tissues. Zhang et al. ([@B76]) revealed that circNRIP1 can sponge miR-149-5p and thus affect the AKT1/mammalian target of rapamycin (mTOR) axis, acting as a tumor promoter in gastric cancer (GC). This study also suggested that circNRIP1 can assemble into exosomes and participate in exosomal communication among GC cells ([@B76]).

Invasion and Metastasis
-----------------------

Recently, Hu et al. ([@B77]) identified a circRNA, circASAP1, that is associated with pulmonary metastasis after curative resection in hepatocellular carcinoma (HCC) patients. Studies have shown that circASAP1 acts as a sponge of miR-326 and miR-532-5p, which have mitogen-activated protein kinase (MAPK)1 and colony stimulating factor (CSF-1) in common as target genes, thereby promoting HCC cell invasion and macrophage infiltration. In addition, Chen et al. ([@B78]) discovered a circRNA, FECR1, derived from Friend leukemia virus integration 1 (FLI1). Overexpression of FECR1 can increase the invasiveness of breast cancer cells. Mechanism studies have shown that FECR1 can recruit TET1 and act in trans to downregulate DNMT1, causing DNA demethylation of FLI1 and promoting cell metastasis. FECR1 may be a potential therapeutic target for metastatic breast cancer. m6A-modified circNSUN2 can form a ternary complex with insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) and high-mobility group A2 (HMGA2) to enhance HMGA2 mRNA stability and subsequently promote liver metastasis in CRC ([@B79]). CircFoxo3 expression is low in high-grade prostate cancer, and overexpression of circFoxo3 in DU145 cells can inhibit the epithelial--mesenchymal transition (EMT) and reduce cell viability by enhancing Foxo3 expression ([@B26]). CircMTO1 (hsa_circRNA_104135) is significantly downregulated in HCC and can affect p21 expression by targeting miR-9 and, in turn, promote cell proliferation and invasion ([@B80]).

Cell Cycle
----------

Circ-Foxo3 has been shown to bind with CDK2 and p21, leading to formation of the circ-Foxo3--p21--CDK2 ternary complex ([@B81]). CDK2 generally interacts with cyclin A/E to promote cell cycle progression, while p21 inhibits these effects. Formation of this ternary complex enhanced the inhibitory effect of p21 on CDK2, which prevented cell cycle transition from G1 to S phase and thus inhibited cell proliferation. Cheng et al. ([@B82]) found significant upregulation of circTP63 in lung squamous cell carcinoma (LUSC) tissues. CircTP63 competitively binds to miR-873-3p, thereby abolishing the inhibitory effect of miR-873-3p on its target gene Forkhead Box M1 (FOXM1). Elevated FOXM1 expression further enhances the expression of centromere protein (CENP)A and CENPB, ultimately promoting cell cycle progression and cell proliferation.

Cell Death
----------

Circ-Foxo3 was reported to be downregulated in tumor tissues and cells ([@B83]). On the one hand, transfection of circ-Foxo3 can induce apoptosis as a stress stimulus. On the other hand, highly expressed circ-Foxo3 interacts with p53 and murine double minute 2 (MDM2) and inhibits ubiquitination-mediated degradation of Foxo3 by MDM2. Overexpression of Foxo3 promotes apoptosis *via* its target Puma. Du et al. ([@B84]) detected abnormally increased circ-Dnmt1 expression in breast cancer tissues and cells and found that circ-Dnmt1 interacted with p53 and AUF1, leading to their nuclear translocation, thus mediating cell autophagy. Transfection of circ-Dnmt1 into breast cancer cells can induce autophagy to maintain cell homeostasis and ultimately promote cell proliferation and tumorigenesis. Furthermore, Chen et al. ([@B85]) found that circHIPK3 expression was upregulated in STK11 mutant lung cancer cell lines. Silencing circHIPK3 can induce autophagy through the miR124-3p--STAT3--PRKAA/AMPKa axis. Thus, circHIPK3 is a key upstream regulator of autophagy in lung cancer.

Others
------

CircRNAs can also regulate the drug sensitivity of tumors. By high-throughput sequencing of circRNAs of five pairs of cisplatin-sensitive and cisplatin-resistant ovarian cancer tissues, Zhao et al. ([@B86]) found that CDR1as was significantly downregulated in cisplatin-resistant tissues. Mechanism studies confirmed that CDR1as can regulate the sensitivity of ovarian cancer to cisplatin through the miR-1270/SCAI signaling pathway and promote ovarian cancer development. In addition, circRNAs derived from fusion genes have been shown to play a special role in cancers. Recent studies have demonstrated that chromosomal translocations in cancer could not only encode oncogenic fusion proteins but also generate circRNAs. This kind of fusion circRNA (f-circRNA) is unique to cancer and may play an important role in tumorigenesis. F-circRNAs were first identified in a study on leukemia, in which F-circPR and F-circM9 (derived from PML-RARα and MLL-AF9 fusion genes, respectively) were found to promote cellular transformation, cell viability, and drug resistance ([@B87]). In addition, F-circEA-2a, derived from the EML4-ALK fusion gene in NSCLC, is located mainly in the cytoplasm and can promote cell migration and invasion ([@B88]). The tumor-suppressive effect of circFAT1 (e2) in GC can simultaneously arise through the cytoplasmic circFAT1 (e2)/miR-548g/RUNX1 axis and the nuclear circFAT1 (e2)/YBN1 regulatory network ([@B89]). Thus, the mechanism of circRNAs *in vivo* is very complicated, and our current knowledge of this process is only nascent. Additional studies are listed in [Table 2](#T2){ref-type="table"}.

###### 

A list of circRNAs related to cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cancer type**                      **CircRNA**        **Mechanism**                 **Target**                                 **Expression in cancer**   **Function**                                                                                                                               **References**
  ------------------------------------ ------------------ ----------------------------- ------------------------------------------ -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ----------------
  Lung cancer                          hsa_circ_0007059   MiRNA sponge                  miR-378/Wnt/β-catenin\                     Down                       Inhibit cell proliferation and EMT, promote apoptosis                                                                                      ([@B90])
                                                                                        miR-378/ ERK1/2                                                                                                                                                                                                  

                                       hsa_circ_103809    MiRNA sponge                  miR-4302/ZNF121/MYC                        Up                         Promote cell proliferation and invasion                                                                                                    ([@B91])

                                       circRNA 100146     MiRNA sponge                  miR-361-3p, miR-615-5p/SF3B3               Up                         Inhibit cell proliferation and invasion, promote apoptosis                                                                                 ([@B92])

                                       circPTK2           MiRNA sponge                  miR-429, miR-200b-3p/ TIF1γ/TGF-β          Down                       Inhibit EMT and metastasis                                                                                                                 ([@B93])

                                       circHIPK3          MiRNA sponge                  miR124-3p/STAT3/PRKAA and AMPKa            Up                         Promote cell proliferation, migration and invasion, inhibit macroautophagy and autophagy                                                   ([@B85])

                                       cESRP1             MiRNA sponge                  miR-93-5p/CDKN1A /TGF-β                    Down                       Increase chemotherapy sensitivity                                                                                                          ([@B94])

                                       cMras              MiRNA sponge                  miR-567/PTPRG                              Down                       Inhibit LUAD growth and metastasis                                                                                                         ([@B95])

  Colorectal cancer                    circNSUN2          Protein scaffolds             IGF2BP2/ HMGA2                             Up                         Promote liver metastasis and cells invasion                                                                                                ([@B79])

                                       circACC1           Protein scaffolds             AMPK                                       Up                         Promote cell proliferation                                                                                                                 ([@B75])

                                       circCCDC66         MiRNA sponge                  miR-33b, miR-93                            Up                         Promote cell proliferation, migration, and metastasis                                                                                      ([@B96])

                                       circHIPK3          MiRNA sponge                  miR-7/ FAK, IGF1R, EGFR, YY1               Up                         Promote cell proliferation, migration and invasion, inhibit cell apoptosis                                                                 ([@B97])

                                       circPPP1R12A       Translation template          circPPP1R12A-73aa/Hippo-YAP                Up                         Promote cell proliferation, migration and invasion                                                                                         ([@B25])

                                       circLgr4           Translation template          circLgr4-peptide /Wnt/β-catenin            Up                         Promote colorectal cancer stem cells (CSCs) self-renewal, colorectal tumorigenesis and invasion                                            ([@B98])

                                       hsa_circ_0053277   MiRNA sponge                  miR-2467-3p/MMP14                          Up                         Promote cell proliferation, migration, and EMT                                                                                             ([@B99])

                                       hsa_circ_0001178   MiRNA sponge                  miR-382, miR-587, miR-616/ZEB1             Up                         Promote cell migration and invasion                                                                                                        ([@B100])

  Gastric cancer                       circNRIP1          MiRNA sponge                  miR-149-5p/AKT1-mTOR                       Up                         Promote cell proliferation, migration, invasion                                                                                            ([@B76])

                                       circPSMC3          MiRNA sponge                  miR-296-5p/PTEN                            Down                       Inhibit the tumorigenesis *in vivo* and *in vitro*                                                                                         ([@B101])

                                       circ-DONSON        Protein scaffolds             NURF/SOX4                                  Up                         Promote cell proliferation, migration and invasion, inhibit apoptosis                                                                      ([@B102])

                                       circYAP1           MiRNA sponge                  miR-367-5p/p27 Kip1                        Down                       Inhibit cell growth and invasion *in vitro* and *in vivo*                                                                                  ([@B103])

                                       circLARP4          MiRNA sponge                  miR-424/LATS1                              Down                       Inhibit cell proliferation and invasion                                                                                                    ([@B104])

                                       circFAT1(e2)       MiRNA sponge                  miR-548g/RUNX1\                            Down                       Promote cell proliferation, migration, and invasion                                                                                        ([@B89])
                                                                                        YBX1                                                                                                                                                                                                             

                                       circDLST           MiRNA sponge                  miR-502-5p/NRAS/MEK1/ERK1/2                Up                         Promote the tumorigenesis and metastasis                                                                                                   ([@B105])

                                       circ-HuR           Protein scaffolds             CNBP/HuR                                   Down                       Inhibit cell growth, invasion, and metastasis                                                                                              ([@B106])

                                       circOSBPL10        MiRNA sponge                  miR-136-5p/WNT2                            Up                         Promote cell growth, migration, and invasion                                                                                               ([@B107])

  Breast cancer                        circKIF4A          MiRNA sponge                  circKIF4A-miR-375-KIF4A                    Up                         Promote cell proliferation and migration                                                                                                   ([@B108])

                                       FECR1              Protein scaffolds             FLI1/TET1                                  Up                         Enhance invasiveness of breast cancer cells                                                                                                ([@B78])

                                       circ-Dnmt1         Protein scaffolds             p53/AUF1                                   Up                         Promote the proliferative and survival capacities of breast cancer cells by stimulating cellular autophagy                                 ([@B84])

                                       circANKS1B         MiRNA sponge                  miR-148a-3p, miR-152-3p/USF1/TGF-β1/Smad   Up                         Promote breast cancer invasion and metastasis                                                                                              ([@B109])

                                       circEPSTI1         MiRNA sponge                  miR-4753, 6809/BCL11A                      Up                         Promote cell proliferation, inhibit apoptosis                                                                                              ([@B94])

                                       circIRAK3          MiRNA sponge                  miR-3607/FOXC1                             Up                         Promote cell migration, invasion and metastasis                                                                                            ([@B110])

                                       circAGFG1          MiRNA sponge                  miR-195-5p/ CCNE1                          Up                         Promote triple-negative breast cancer (TNBC) cell proliferation, mobility and invasion as well as tumorigenesis and metastasis *in vivo*   ([@B111])

                                       circFBXW7          Translation template          FBXW7-185aa/c-Myc                          Down                       Inhibit proliferation and migration abilities of TNBC cells                                                                                ([@B112])

  HCC                                  cSMARCA5           MiRNA sponge                  miR-17-3p, miR-181b-5p/TIMP3               Down                       Inhibit cell proliferation and migration of HCC cells                                                                                      ([@B113])

                                       circMTO1           MiRNA sponge                  miR-9/p21                                  Down                       Inhibit cell proliferation and invasion                                                                                                    ([@B80])

                                       circ-CDYL          MiRNA sponge                  miR-892a/HDGF, miR-328-3p/HIF1AN           Up                         Promote tumor growth                                                                                                                       ([@B114])

                                       circβ-catenin      Translation template          β-catenin/Wnt                              Up                         Promote malignant phenotypes *in vitro* and *in vivo*                                                                                      ([@B74])

                                       circSLC3A2         MiRNA sponge                  miR-490-3p/PPM1F                           Up                         Promote HCC cell proliferation and invasion                                                                                                ([@B115])

                                       circHIPK3          MiRNA sponge                  miR-124/AQP3                               Up                         Promote cell proliferation and migration                                                                                                   ([@B116])

                                       circRHOT1          Protein scaffolds             TIP60/NR2F6                                Up                         Promote proliferation and metastasis                                                                                                       ([@B116])

                                       circTRIM33-12      MiRNA sponge                  miR-191/TET1                               Down                       Inhibit proliferation, migration, invasion and immune evasion abilities of HCC cells                                                       ([@B117])

  Ovarian cancer                       circPLEKHM3        MiRNA sponge                  miR-9/BRCA1/DNAJB6 /KLF4/AKT1              Down                       Inhibit cell growth, migration and EMT                                                                                                     ([@B118])

                                       hsa_circ_0061140   MiRNA sponge                  miR-370/FOXM1                              Up                         Promote cell proliferation and migration                                                                                                   ([@B119])

                                       hsa_circ_0051240   MiRNA sponge                  miR-637/KLK4                               Up                         Promote cell proliferation, migration and invasion                                                                                         ([@B120])

                                       circWHSC1          MiRNA sponge                  miR-145/ MUC1\                             Up                         Promote cell proliferation, migration and invasion, inhibit cell apoptosis                                                                 ([@B121])
                                                                                        miR-1182/hTERT                                                                                                                                                                                                   

  Prostate cancer                      circFoxo3          Modulators of transcription   Foxo3                                      Down                       Inhibit prostate cancer viability and EMT                                                                                                  ([@B26])

                                       circZNF609         MiRNA sponge                  miR-186-5p/YAP1/AMPK                       Up                         Promote growth, migration and invasion                                                                                                     ([@B122])

                                       circ0005276        Modulators of transcription   FUS/XIAP                                   Up                         Promote cell proliferation, migration and EMT                                                                                              ([@B123])

  Pancreatic cancer                    circZMYM2          MiRNA sponge                  miR-335-5p/JMJD2C                          Up                         Promote cell proliferation and invasion, inhibit cell apoptosis                                                                            ([@B124])

                                       hsa_circ_0000977   MiRNA sponge                  miR-874-3p/PLK1                            Up                         Promote pancreatic cancer growth                                                                                                           ([@B125])

                                       circ-ASH2L         MiRNA sponge                  miR-34a/Notch 1                            Up                         Promote tumor invasion, proliferation and angiogenesis                                                                                     ([@B126])

  Glioblastoma                         circNT5E           MiRNA sponge                  miR-422a                                   Up                         Promote cell proliferation, migration and invasion                                                                                         ([@B127])

                                       circMMP9           MiRNA sponge                  miR-124/CDK4/AURKA                         Up                         Promote cell proliferation, migration and invasion                                                                                         ([@B128])

  Bladder cancer                       BCRC-3                                           miR-182-5p/p27                             Down                       Inhibit cell proliferation                                                                                                                 ([@B73])

  Esophageal squamous cell carcinoma   ciRS-7             MiRNA sponge                  miR-7/HOXB13/NF-κB/p65                     Up                         Inhibit cell proliferation, migration and invasion                                                                                         ([@B129])

  Gallbladder cancer                   circERBB2          Protein scaffolds             PA2G4/TIFIA                                Up                         Modulate ribosomal DNA transcription and cell proliferation                                                                                ([@B130])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*circRNA, circular RNA; EMT, epithelial--mesenchymal transition; HCC, hepatocellular carcinoma; LUAD, lung adenocarcinoma*.

circRNAs as Biomarkers in Cancer {#s7}
================================

CircRNAs have a covalently closed circular structure, which increases their resistance to exonuclease digestion and their accumulation in body fluids and tissues ([@B131], [@B132]). In addition, circRNAs are often expressed in a tissue- and developmental stage-specific manner. The properties of circRNAs have inspired numerous studies on their application as promising biomarkers in cancer.

Diagnostic Biomarkers
---------------------

### circRNAs in Tissues

Wei et al. ([@B114]) found that circ-CDYL and its target genes (HDGF and HIF1AN) were highly expressed in Barcelona Clinic Liver Cancer (BCLC) stages 0 and A of HCC. Their sensitivity and specificity as combined biomarkers were higher than those of alpha-fetoprotein (AFP) in the early stage of HCC. These results indicated that a panel combining circ-CDYL with HDGF and HIF1AN could be used as a monitoring indicator for early HCC or high-risk populations. In addition, Zhong et al. ([@B133]) detected highly expressed CDR1as in nasopharyngeal carcinoma (NPC) biopsy samples. However, unfortunately, current methods for detecting circRNAs in tissue are complex and invasive, which greatly limit their roles in the early diagnosis and screening of cancer.

### circRNAs in Peripheral Blood

Numerous studies have confirmed that circRNAs can be stably enriched in peripheral blood, urine, and saliva. Therefore, circRNAs could become suitable biomarkers for liquid biopsy. Recently, a study on the use of plasma circRNAs in the diagnosis of hepatitis B virus (HBV)-associated HCC was published ([@B134]). This study included 1,195 plasma samples, which were divided into a training set and two validation sets. The researchers found that the plasma expression levels of hsa_circ_0000976, hsa_circ_0007750, and hsa_circ_0139897 in HCC patients were significantly higher than those in healthy controls and patients with chronic hepatitis B or HBV-related liver cirrhosis. They also designed an HCC prediction model named CircPanel through binary logistic regression analysis. CircPanel showed higher sensitivity and specificity (both higher than 80%) than AFP level for distinguishing HCC patients from controls. Notably, CircPanel can also diagnose AFP-negative HCC and AFP-negative small HCC (solitary, diameter ≤3 cm) with high diagnostic accuracy. In another study, Lin et al. ([@B135]) found that the plasma levels of circ-CCDC66, circ-ABCC1, and circ-STIL were significantly decreased in CRC patients compared with controls. The combination of these three circRNAs had a sensitivity and specificity of 64.4% and 85.2%, respectively, for diagnosing CRC. Notably, f-circRNAs derived from fusion genes are generally cancer-specific and thus have high specificity in diagnosing cancer, which is a unique advantage for tumor biomarkers. Tan et al. ([@B136]) reported a fusion circRNA named F-circEA derived from an EML4-ALK fusion gene that was positively expressed in five of six NSCLC patients with EML4-ALK translocation. F-circEA also exists specifically in the plasma of EMLA4-ALK-positive NSCLC patients.

### circRNAs in Exosomes

Exosomal circRNAs have received gradually increasing attention in recent years. Li et al. ([@B137]) identified more than 1,000 circRNAs in human serum exosomes for the first time and suggested that these circRNAs could distinguish between colon cancer patients and healthy controls. Pan et al. ([@B138]) used qRT-PCR to detect hsa-circ-0004771 in circulating exosomes from 170 patients and 45 healthy controls and confirmed that hsa-circ-0004771 could clearly distinguish between patients with stage I/II CRC and those with benign intestinal diseases. Li et al. ([@B139]) detected high expression of circ-PDE8A in liver-metastatic pancreatic ductal adenocarcinoma (PDAC) tissues, and this characteristic was confirmed to be closely related to lymphatic infiltration, T status, and TNM stage. Circ-PDE8A is an independent risk factor for the survival of PDAC patients. Further research confirmed the presence of circ-PDE8A-rich exosomes secreted from tumor cells in the plasma of PDAC patients. Similarly, circ-PDE8A in plasma exosomes may also be a diagnostic and prognostic marker for PDAC.

### circRNAs in Other Body Fluids

The use of circRNAs in other body fluid samples has also been studied. For example, gastric juice examination is a highly organ-specific test for the diagnosis of gastric diseases. Shao et al. ([@B140]) explored the feasibility of hsa_circ_0014717 in gastric juice as a biomarker for screening patients with GC. The expression of hsa_circ_0014717 in gastric juice from 38 healthy people, 30 patients with gastric ulcers, 15 patients with chronic atrophic gastritis, and 39 patients with GC was measured by qRT-PCR. Hsa_circ_0014717 was significantly downregulated in patients with chronic atrophic gastritis compared with healthy controls, suggesting the potential utility of hsa_circ_0014717 in gastric juice as a biomarker for screening high-risk populations for GC. In addition, saliva is a body fluid used for disease research due to its convenient and noninvasive sampling method. Bahn et al. ([@B141]) detected and verified the presence of circRNAs in cell-free saliva, which suggested a new direction for the application of circRNAs as biomarkers. Moreover, Chen et al. ([@B142]) detected highly expressed circPRMT5 in exosomes isolated from urine samples from patients with urothelial carcinoma of the bladder (UCB). Additional studies are listed in [Table 3](#T3){ref-type="table"}.

###### 

CircRNAs as diagnostic biomarkers in cancer.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cancer type**     **CircRNA**                                               **Source**            **Cohort size**   **Expression in cancer**   **AUC**   **Sensitivity %**   **Specificity %**   **Relationship with other biomarkers**                                                                                              **References**
  ------------------- --------------------------------------------------------- --------------------- ----------------- -------------------------- --------- ------------------- ------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------
  HCC                 circZKSCAN1                                               Tissue                102               Down                       0.834     82.2                72.4                --                                                                                                                                  ([@B143])

                      circ_104075                                               Tissue                89                Down                       0.973     96.0                98.3                Perform better than DANCR, HULC, miR-223, miR-21, UCA1, AFP, DCP, and AFP-L3-                                                       ([@B144])

                      circSMARCA5                                               Plasma                489               Down                       0.938     --                  --                  When combined with AFP, the AUC increased to 0.903 and 0.858 in detecting HCC from hepatitis and cirrhosis, respectively            ([@B145])

                      hsa_circ_0000976, hsa_circ_0007750 and hsa_circ_0139897   Plasma                1195              Up                         0.863\    --                  --                  Perform better than AFP in diagnosing HCC and SmallHCC                                                                              ([@B134])
                                                                                                                                                   0.843\                                                                                                                                                                                
                                                                                                                                                   0.864                                                                                                                                                                                 

                      Circ-CDYL                                                 Tissue                149               Up                         0.73      75.36               66.67               Perform better than AFP in diagnosing early stage of HCC                                                                            ([@B114])

  Gastric cancer      hsa_circ_0000745                                          Plasma                120               Down                       0.683     85.5                45.0                When combined with CEA, the AUC increased to 0.775, while the sensitivity and specificity changed to 0.800 and 0.633                ([@B146])

                      hsa_circ_0000520                                          Tissue                56                Down                       0.6129    53.57               85.71               --                                                                                                                                  ([@B147])

                      hsa_circ_0000520                                          Plasma                62                Down                       0.8967    82.35               84.44               Associated with CEA                                                                                                                 ([@B147])

                      hsa_circ_0014717                                          Tissue                96                Down                       0.696     59.38               81.25               Associated with CEA and CA19-9                                                                                                      ([@B140])

                      hsa_circ_0000096                                          Tissue                101               Down                       0.82      --                  --                  When combined with hsa_circ_002509, the AUC increased to 0.91, while the sensitivity and specificity changed to 0.800 and 0.633     ([@B148])

  Lung cancer         hsa_circ_0013958                                          Tissue                49                Up                         0.815     75.5                79.6                --                                                                                                                                  ([@B149])

                      hsa_circ_0075930                                          Tissue                92                Up                         0.756     76.2                72.1                --                                                                                                                                  ([@B150])

                      circRNA_102231                                            Tissue                57                Up                         0.897     81.2                88.7                --                                                                                                                                  ([@B151])

                      circFARSA                                                 Plasma                100               Up                         0.71      --                  --                  --                                                                                                                                  ([@B71])

  Colorectal cancer   circ-CCDC66, circ-ABCC1and circ-STIL                      Plasma                106               Down                       0.78      64.4                85.2                When combined with CEA and CA19-9, the AUC increased to 0.855 in detecting CRC                                                      ([@B135])

                      circVAPA                                                  Plasma                103               Up                         0.724     --                  --                  --                                                                                                                                  ([@B152])

                      circITGA7                                                 Tissue                69                Down                       0.8791    92.75               66.67               --                                                                                                                                  ([@B153])

                      hsa-circ-0004771                                          Circulating exosome   215               Up                         0.88      80.91               82.86               --                                                                                                                                  ([@B138])

  Pancreatic cancer   circ-LDLRAD3                                              Plasma                62                Up                         0.67      57.38               70.49               When combined with CA19-9, the AUC was increased to 0.87 and the sensitivity and specificity were 0.8033 and 0.9355, respectively   ([@B154])

  Osteosarcoma        circPVT1                                                  Serum                 90                Up                         0.871     --                  --                  Perform better than ALP and LDH                                                                                                     ([@B155])
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*AFP, alpha-fetoprotein; circRNA, circular RNA; HCC, hepatocellular carcinoma*.

Prognostic Biomarkers
---------------------

### circRNAs Predict Patient Survival

CircRNAs have wide application prospects in monitoring the treatment efficacy and assessing the prognosis of cancer. By using RNA-seq to identify circRNAs related to HCC progression, Qiu et al. ([@B156]) determined that circADAMTS13 was significantly downregulated in HCC tissues compared with matched nontumor tissues. Moreover, its expression was positively associated with recurrence-free survival (RFS). Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of circADAMTS13 in HCC patients, and the area under ROC curve (AUC) was 0.987. He et al. ([@B157]) determined that circGFRA1 was significantly upregulated in triple-negative breast cancer via circRNA microarray analysis. In addition, Kaplan--Meier survival analysis showed that upregulation of circGFRA1 was associated with poorer clinical survival. CircHIPK3 is significantly upregulated in CRC tissues and cell lines and is associated with the T status of tumors, lymph node and distant metastasis, and advanced clinical stage ([@B97]). High expression of circHIPK3 in CRC is an independent prognostic factor for poor overall survival (OS). Compared with paired noncancerous tissues, GC tissues exhibit significant downregulation of hsa_circ_0000096; moreover, the AUC increased from 0.82 to 0.91 when hsa_circ_0000096 was combined with hsa_circ_002509 ([@B148]). Analysis of 90 paired samples of NSCLC and adjacent normal tissues showed that hsa_circ_0014130 was significantly upregulated in NSCLC and was found to be related to tumor size, TNM stage, and lymphatic metastasis ([@B158]). ROC analysis indicated that hsa_circ_0014130 might be a prognostic biomarker in NSCLC.

In addition to identifying the differential expression of hsa_circ_002059 in GC and adjacent tissues, Li et al. ([@B159]) also found that the expression levels of hsa_circ_002059 in 36 pairs of matched plasma samples from preoperative and postoperative GC patients were significantly different. Considering that circRNAs can be secreted into the tumor microenvironment and the circulatory system by tumor cells, it is reasonable to speculate that circRNAs can be used as biomarkers to evaluate the tumor-bearing status of patients. As mentioned above, circHIPK3 can regulate the autophagy process in lung cancer through the miR124-3p--STAT3--PRKAA/AMPKa axis ([@B85]). In addition, researchers found that the ratio (C:L ratio) of circHIPK3 to linear HIPK3 (linHIPK3) can reflect the level of autophagy in cells---a higher C:L ratio indicates a lower level of autophagy and poorer prognosis.

circRNAs Predict Not Only Tumor Metastasis but Also Drug Resistance
-------------------------------------------------------------------

Recent studies have also reported that circRNAs can predict tumor metastasis and drug resistance. Xu et al. ([@B160]) analyzed the circRNA expression profile of three pairs of CRC patients with or without liver metastasis. Further verification demonstrated that circRNA_0001178 and circRNA_0000826 were significantly upregulated in metastatic CRC (CRC-m) tissues. The AUCs were 0.945 for circRNA_0001178 and 0.816 for circRNA_0000826, and both two circRNAs could differentiate liver metastases from CRC. CircASAP1 is highly expressed in the tissues of HCC patients with pulmonary metastases after curative resection ([@B77]), and its expression is positively correlated with the levels of CSF-1, MAPK1, and CD68^+^ tumor-associated macrophage. Patients with high circASAP1 expression tend to have relatively low OS and high recurrence rates. Therefore, circASAP1 can be used as a prognostic indicator for HCC.

In addition, cisplatin is one of the main chemotherapeutic drugs used to treat GC. Huang et al. ([@B161]) analyzed the correlation between the clinical efficacy of cisplatin and circRNA expression in 105 cisplatin-treated patients, and they found that the expression of circAKT3 in cisplatin-resistant patients was higher than that in cisplatin-sensitive patients. CircAKT3 is an effective predictive biomarker for cisplatin resistance in GC patients (AUC = 0.91). Confirmation of the relationships between circRNA expression and drug sensitivity would provide guidance for reasonable clinical medication and thus improve patient prognosis. Additional studies are listed in [Table 4](#T4){ref-type="table"}.

###### 

CircRNAs as prognostic biomarkers in cancer (cohort size ≥50).

  **Cancer type**            **CircRNA**          **Source**        **Cohort size**   **Expression in cancer**   **Clinical significance**                                                                                                                 **References**
  -------------------------- -------------------- ----------------- ----------------- -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Hepatocellular carcinoma   circADAMTS13         Tissue            102               Down                       Negatively associated with tumor size, BCLC stage; Positively associated with RFS                                                         ([@B156])
                             SCD-circRNA 2        Tissue            151               Up                         Negatively associated with RFS and OS; Positively associated with RFS                                                                     ([@B162])
                             circRNA_100338       Tissue            80                Up                         Negatively associated with OS; Positively associated with TNM stage, vascular invasion and lung metastasis                                ([@B163])
                             circRNA 101368       Tissue            51                Up                         Negatively associated with OS; Positively associated with distant metastasis, TNM stage, tumor size                                       ([@B164])
                             circ-10720           Tissue            381               Up                         Negatively associated with survival; Positively associated with clinical stage, pathology grade, AFP level and hepatitis B markers        ([@B165])
                             circSMARCA5          Tissue            197               Down                       Negatively associated with TNM stage, tumor invasion and tumor size; Positively associated with tumor differentiation                     ([@B145])
  Gastric cancer             circLARP4            Tissue            80                Down                       Negatively associated with tumor size and lymphatic metastasis; Positively associated with OS                                             ([@B104])
                             hsa_circ_0001368     Tissue            68                Down                       Positively associated with prognosis                                                                                                      ([@B166])
                             circPVT1             Tissue            187               Up                         Positively associated with OS and DFS                                                                                                     ([@B28])
                             circNRIP1            Tissue            80                Up                         Negatively associated with OS and DFS; Positively associated with tumor size and lymphatic invasion                                       ([@B76])
                             circ-KIAA1244        Plasma            87                Down                       Negatively associated with OS; Positively associate with TNM stage and lymphatic metastasis, and poor overall survival time               ([@B167])
                             circAKT3             Tissue            149               Up                         Positively associate with cisplatin resistance                                                                                            ([@B161])
  Lung cancer                ciRS-7               Tissue            132               Up                         Negatively associated with OS and DFS; Positively associated with tumor size, lymph node metastasis and TNM stage                         ([@B168])
                             circ-PRMT5           Tissue            90                Up                         Negatively associated with OS and progression-free survival; Positively associated with tumor size, lymph node metastasis and TNM stage   ([@B169])
                             circPTK2             Tissue            73                Down                       Positively associated with metastatic NSCLC Tissues                                                                                       ([@B93])
                             circ_0016760         Tissue            83                Up                         Negatively associated with OS; Positively associated with TNM stage and lymph node metastasis                                             ([@B170])
                             hsa_circ_0000064     Tissue            50                Up                         Positively associated with TNM stage and lymphatic metastasis                                                                             ([@B171])
  Breast cancer              hsa_circRNA_002178   Tissue            70                Up                         Negatively associated with survival                                                                                                       ([@B172])
                             circ_0005230         Tissue            76                Up                         Negatively associated with OS; Positively associated with tumor size, TNM stage and lymph node metastasis                                 ([@B173])
                             circKIF4A            Tissue            240               Up                         Negatively associated with survival                                                                                                       ([@B108])
                             circGFRA1            Tissue            51                Up                         Negatively associated with survival                                                                                                       ([@B157])
  Colorectal cancer          CircCCDC66           Tissue            229               Up                         Negatively associated with OS                                                                                                             ([@B96])
                             circHIPK3            Tissue            178               Up                         Negatively associated with OS; Positively associated with metastasis and advanced clinical stage                                          ([@B97])
                             circVAPA             Tissue            60                Up                         Positively associated with lympho-vascular invasion, depth of invasion, lymph node metastasis, distant metastasis and TNM stage           ([@B152])
  Bladder cancer             circMTO1             Tissue            117               Up                         Negatively associated with OS and DFS; Positively associated with lymph node metastasis                                                   ([@B174])
                             cTFRC                Tissue            220               Up                         Negatively associated with prognosis; Positively associated with tumor grade and T stage                                                  ([@B175])
  Pancreatic cancer          circ-IARS            Tissue            79                Up                         Negatively associated with survival; Positively associated with liver metastasis, vascular invasion, and TNM stage                        ([@B176])
                             circ-PDE8A           Plasma exosomes   56                Up                         Negatively associated with survival; Positively associated with duodenal invasion, vascular invasion, T factor and TNM stage              ([@B139])
  Ovarian cancer             circPLEKHM3          Tissue            86                Down                       Positively associated with OS and RFS                                                                                                     ([@B118])
                             circWHSC1            Tissue            92                Up                         Negatively associated with differentiation                                                                                                ([@B121])
  Osteosarcoma               hsa_circ_0081001     Tissue            82                Up                         Negatively associated with clinical outcome                                                                                               ([@B177])
  Nasopharyngeal carcinoma   CDR1as               Biopsy            64                Up                         Positively associated with survival                                                                                                       ([@B133])
  Glioma                     circ_0034642         Tissue            68                Up                         Negatively associated with survival; Positively associated with tumor size and advanced WHO grade                                         ([@B178])

*AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; circRNA, circular RNA; DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival*.

Conclusions and Perspectives {#s8}
============================

As the understanding of circRNAs has increased, their perception by the scientific community has changed dramatically. CircRNAs are not "splicing noise" but rather a class of structurally stable RNA molecules with multiple biological functions. circRNAs are generally derived from back-splicing of pre-mRNA and are widely expressed across biological systems.

The relationship between circRNAs and cancer has recently become an area of research interest. Numerous circRNAs are dysregulated and play regulatory roles in the development of cancer. Several examples of research on the roles of circRNAs in cancer are given above. In summary, circRNAs, through various signaling pathways, can participate in and affect processes related to cell proliferation, migration and invasion, apoptosis, autophagy, and drug resistance, as well as others. This capacity has inspired researchers to consider the therapeutic possibilities of targeting circRNAs and their associated pathways. In addition, researchers have also tried to synthesize artificial circRNAs for disease treatment. For example, an artificial circRNA with eight miRNA-122 binding sites was used to competitively bind to miRNA-122, which is required for the hepatitis C virus (HCV) life cycle, thereby inhibiting the propagation of HCV, with an efficiency comparable to that of the anti-miR drug miravirsen ([@B179]). This study proposed the idea that engineered circRNAs could be used for disease-specific treatments, similar to targeted drugs; however, this idea is far from clinical translation. Due to their stable structure, conservative sequence, and specific expression pattern, circRNAs have the potential to be used as biomarkers for cancer. circRNAs have wide clinical application prospects---from diagnostic assessments to predicting patient prognosis and treatment response. However, most related studies have been single-center and retrospective works.

The study of circRNAs is just beginning, and the mechanism of circRNA biogenesis is not well understood. Even though a few circRNAs have been functionally characterized, our understanding of circRNAs remains incomplete. In addition to the identified functions as miRNA sponges, protein scaffolds, translation templates, and transcriptional regulators, other mechanisms are awaiting discovery, and the cooperation and the relative importance of these mechanisms cannot be evaluated at present. In addition, the transport and degradation mechanisms of circRNAs are poorly understood. Therefore, much work remains to be done. The discovery of circRNAs has undoubtedly enriched the content of RNA regulatory networks and has offered new approaches for the development of clinically translatable diagnostic/prognostic biomarkers and therapeutic targets for cancer.
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